Differential susceptibility of gastric cancer cells to TRAIL-induced apoptosis

Song,Nak-Mi; Jun,Suyeon; Zang,Dae  Young; Kim,Sung  Gyun; Park,Hye-Rim; Kang,Dongchul

doi:10.3892/or.2012.2183

Differential susceptibility of gastric cancer cells to TRAIL-induced apoptosis

Authors:
- Nak-Mi Song
- Suyeon Jun
- Dae Young Zang
- Sung Gyun Kim
- Hye-Rim Park
- Dongchul Kang
View Affiliations

Affiliations: Ilsong Institute of Life Science, Hallym University, Anyang, Kyonggi-do 431-060, Republic of Korea, Department of Internal Medicine, Hallym University Medical School and Hallym University Sacred Heart Hospital, Anyang, Kyonggi-do 431-060, Republic of Korea, Department of Pathology, Hallym University Medical School and Hallym University Sacred Heart Hospital, Anyang, Kyonggi-do 431-060, Republic of Korea
Published online on: December 11, 2012 https://doi.org/10.3892/or.2012.2183
Pages: 1224-1230

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Understanding the molecular basis of the differential sensitivity of cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis is required to predict therapeutic outcomes and to improve the effectiveness of TRAIL-based therapy. This study aimed to compare the responsiveness of gastric cancer cells to TRAIL treatment and to investigate the molecular basis of the differential TRAIL sensitivity of four gastric cancer cell lines. The TRAIL sensitivity of the four cell lines was ranked in the following order: SNU-16 ≈ SNU-620 > SNU-5 >> SNU-1. The level of Annexin V binding and the activation profile of caspase-3, -8 and -9 corroborated the differential TRAIL susceptibility of the cell lines. To determine the molecular basis of the differential sensitivity to TRAIL, we examined the expression of signaling components involved in TRAIL-mediated apoptosis. The mRNA level and surface expression of death receptor 4 (DR4) were significantly decreased in the SNU-1 cells compared to the other cell lines. Bid cleavage and X-linked inhibitor of apoptosis (XIAP) degradation were significantly increased in the SNU-16 and SNU-620 cells compared to the SNU-5 and SNU-1 cells, although Bid and XIAP were expressed at similar levels across the four cell lines. The expression and degradation of FLICE-inhibitory protein (FLIP) upon TRAIL treatment was independent of TRAIL sensitivity. In conclusion, the differential susceptibility of the four gastric cancer cells to TRAIL may be ascribed to the differential expression of DR4 and the proper augmentation of the death signal by the truncation of Bid and degradation of XIAP.

View Figures

View References

1	Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682. 1995. View Article : Google Scholar : PubMed/NCBI
2	Bouralexis S, Findlay DM and Evdokiou A: Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis. 10:35–51. 2005. View Article : Google Scholar : PubMed/NCBI
3	Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI
4	Almasan A and Ashkenazi A: Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14:337–348. 2003. View Article : Google Scholar : PubMed/NCBI
5	Zauli G and Secchiero P: The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev. 17:245–257. 2006. View Article : Google Scholar : PubMed/NCBI
6	Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
7	Xiang H, nguyen CB, Kelley SK, Dybdal N and Escandon E: Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos. 32:1230–1238. 2004. View Article : Google Scholar
8	Johnstone RW, Frew AJ and Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 8:782–798. 2008. View Article : Google Scholar : PubMed/NCBI
9	Zhang L and Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12:228–237. 2005. View Article : Google Scholar : PubMed/NCBI
10	Hopkins-Donaldson S, Ziegler A, Kurtz S, et al: Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 10:356–364. 2003. View Article : Google Scholar : PubMed/NCBI
11	Kim K, Fisher MJ, Xu SQ and el-Deiry WS: Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res. 6:335–346. 2000.PubMed/NCBI
12	Ozoren N, Fisher MJ, Kim K, et al: Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol. 16:917–925. 2000.PubMed/NCBI
13	Wajant H, Pfizenmaier K and Scheurich P: TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis. 7:449–459. 2002. View Article : Google Scholar : PubMed/NCBI
14	Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S and Sanlioglu S: Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 5:542005. View Article : Google Scholar : PubMed/NCBI
15	Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B and Bunz F: X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res. 64:3006–3008. 2004. View Article : Google Scholar
16	Nam SY, Jung GA, Hur GC, et al: Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci. 94:1066–1073. 2003. View Article : Google Scholar : PubMed/NCBI
17	Sun SY, Yue P, Zhou JY, et al: Overexpression of Bcl2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun. 280:788–797. 2001. View Article : Google Scholar : PubMed/NCBI
18	Chen JJ, Knudsen S, Mazin W, Dahlgaard J and Zhang B: A 71-gene signature of TRAIL sensitivity in cancer cells. Mol Cancer Ther. 11:34–44. 2012. View Article : Google Scholar : PubMed/NCBI
19	Mahalingam D, Szegezdi E, Keane M, de Jong S and Samali A: TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev. 35:280–288. 2009. View Article : Google Scholar : PubMed/NCBI
20	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
21	Cervantes A, Rosello S, Roda D and Rodriguez-Braun E: The treatment of advanced gastric cancer: current strategies and future perspectives. Ann Oncol. 19(Suppl 5): v103–v107. 2008. View Article : Google Scholar : PubMed/NCBI
22	Yoong J, Michael M and Leong T: Targeted therapies for gastric cancer: current status. Drugs. 71:1367–1384. 2011. View Article : Google Scholar : PubMed/NCBI
23	Qiao L and Wong BC: Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist Updat. 12:55–64. 2009. View Article : Google Scholar : PubMed/NCBI
24	Belkhiri A, Zhu S, Chen Z, Soutto M and El-Rifai W: Resistance to TRAIL Is Mediated by DARPP-32 in Gastric Cancer. Clin Cancer Res. 18:3889–3900. 2012. View Article : Google Scholar : PubMed/NCBI
25	Qu J, Zhao M, Teng Y, et al: Interferon-alpha sensitizes human gastric cancer cells to TRAIL-induced apoptosis via activation of the c-CBL-dependent MAPK/ERK pathway. Cancer Biol Ther. 12:494–502. 2011. View Article : Google Scholar : PubMed/NCBI
26	Liu J, Qu XJ, Xu L, et al: Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells. Dig Dis Sci. 55:3361–3368. 2010. View Article : Google Scholar : PubMed/NCBI
27	Huynh KM, Soh JW, Dash R, Sarkar D, Fisher PB and Kang D: FOXM1 expression mediates growth suppression during terminal differentiation of HO-1 human metastatic melanoma cells. J Cell Physiol. 226:194–204. 2011. View Article : Google Scholar
28	Uno K, Inukai T, Kayagaki N, et al: TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood. 101:3658–3667. 2003. View Article : Google Scholar : PubMed/NCBI
29	Hornle M, Peters N, Thayaparasingham B, Vorsmann H, Kashkar H and Kulms D: Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Oncogene. 30:575–587. 2011. View Article : Google Scholar : PubMed/NCBI
30	Park JG, Frucht H, LaRocca RV, et al: Characteristics of cell lines established from human gastric carcinoma. Cancer Res. 50:2773–2780. 1990.PubMed/NCBI
31	Park JG, Yang HK, Kim WH, et al: Establishment and characterization of human gastric carcinoma cell lines. Int J Cancer. 70:443–449. 1997. View Article : Google Scholar : PubMed/NCBI
32	Koyama S, Koike N and Adachi S: Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J Cancer Res Clin Oncol. 128:73–79. 2002. View Article : Google Scholar
33	Lee KH, Lim SW, Kim HG, et al: Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma. Langenbecks Arch Surg. 394:661–670. 2009. View Article : Google Scholar : PubMed/NCBI
34	Park WS, Lee JH, Shin MS, et al: Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology. 121:1219–1225. 2001. View Article : Google Scholar : PubMed/NCBI
35	Fisher MJ, Virmani AK, Wu L, et al: Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res. 7:1688–1697. 2001.PubMed/NCBI
36	Lemke J, Noack A, Adam D, et al: TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J Mol Med. 88:729–740. 2010. View Article : Google Scholar : PubMed/NCBI
37	Szliszka E, Mazur B, Zydowicz G, Czuba ZP and Krol W: TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells. Folia Histochem Cytobiol. 47:579–585. 2009.PubMed/NCBI
38	Aggarwal BB, Bhardwaj U and Takada Y: Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm. 67:453–483. 2004. View Article : Google Scholar : PubMed/NCBI
39	Goncharenko-Khaider N, Lane D, Matte I, Rancourt C and Piche A: The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene. 29:5523–5536. 2010. View Article : Google Scholar : PubMed/NCBI
40	Seal S, Hockenbery DM, Spaulding EY, Kiem HP, Abbassi N and Deeg HJ: Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals. Exp Hematol. 36:1660–1672. 2008. View Article : Google Scholar
41	Zhang XD, Franco A, Myers K, Gray C, Nguyen T and Hersey P: Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 59:2747–2753. 1999.PubMed/NCBI